Health Canada authorises Dexcom G7 15 Day CGM
The device demonstrates a MARD of 8% and includes a 12-hour grace period and mobile app compatibility.
News
Claria Medical secures FDA De Novo classification for hysterectomy device
En Carta secures $6.18m to expand molecular testing solutions
Virax Biolabs enters immune profiling product supply deal with Fosun
Roche secures CE Mark for Elecsys test to detect tuberculosis
TRiCares begins US IDE pivotal trial of TTVR system
Johnson & Johnson’s DE STSF platform secures FDA approval
Philips expands ultrasound portfolio with AI-driven Alturion
